Downregulation the expression of miR-181 promotes RAS-mutated thyroid cancer apoptosis by activating the RASSF1A expression using Intelligent Medical Instruments and Medical Robots

Abstract

Purpose: This paper investigated the mechanism of downregulation of miR181 in papillary thyroid cancer (PTC) tumor cells to activate the expression of RASSF1A protein thus promoting the apoptosis of tumor cells. Methods: The expression of miR-181 was tested by real-time polymerase chain reaction (RT-PCR). Flow Cytometry (FACS) was used to determine the apoptosis ratio of cancer cells respectively. It was detected by Western blot that the RASSF1A protein expression was regulated by miR-181 in PTC cells. Xenograft mouse model is used to measure the change of tumor volume. Possible Results: The possible results are: Downregulation of miR181 activated RASSF1A expression and thus promotes the apoptosis of tumor cells; Downregulation of miR181 only activated RASSF1A expression but did not promote the apoptosis of tumor cells; Downregulation of miR181 neither activated RASSF1A expression nor promotes the apoptosis of tumor cells. Conclusion: Our experiment investigated the activation of the suppressed basal tumor suppressor gene RASSF1A targeting thyroid cancer with miR181 as a regulator. Future studies can focus on finding more small molecules that regulate RASSF1 and the mechanism of action of the RASSF1 gene to explore the method of targeted therapy for other cancers caused by RAS mutations, including thyroid cancer.